Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly ( LLY 0.36%) has been a great growth pick for investors over the past few years. The pharma company, thanks to its ...

Millions of Americans use GLP-1s, and many have relied on versions produced by compounding pharmacies because of the high monthly costs for brand names like Mounjaro and Zepbound.

Novo Nordisk, the maker of Ozempic and Wegovy weight-loss drugs, just regained the title as Europe’s most valuable company ...

Influencers on TikTok have been banned after they were found to be promoting drugs like Ozempic and Mounjaro through their social media ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

The Danish drugmaker, which is grappling with a share decline and competition from Eli Lilly, unveiled planned trials of an ...

A 28-year-old man who started using the injectable medication on Saturday (7 June) has opened up on his experience so far ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

A new study found that weight-loss medications like Ozempic and Mounjaro are not as effective in a “real-world” setting ...